SCAT Trial

Jump to navigation Jump to search

High Density Lipoprotein Microchapters

Home

Patient information

Overview

Historical Perspective

Classification

Physiology

Pathophysiology

Causes

Low HDL
High HDL

Epidemiology and Demographics

Screening

Natural History, Complications and Prognosis

Diagnosis

HDL Laboratory Test

Treatment

Medical Therapy

Prevention

Future or Investigational Therapies

Clinical Trials

Landmark Trials

List of All Trials

Case Studies

Case #1

SCAT Trial On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of SCAT Trial

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on SCAT Trial

CDC on SCAT Trial

SCAT Trial in the news

Blogs on SCAT Trial

Directions to Hospitals Treating High density lipoprotein

Risk calculators and risk factors for SCAT Trial

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Objective

To assess the effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis in normocholesterolemic patients.

Methods

The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT) was a multicentered, randomized, double blinded, placebo-controlled angiographic trial wherein a total of 460 normocholesterolemic patients were enrolled. 230 received simvastatin, 230 a simvastatin placebo, 229 enalapril and 231 an enalapril placebo. All the patients were followed up for an average time period of 47.8 months.

Results

Less progression was observed in patients receiving simvastatin compared to those receiving placebo. On quantitative coronary angiography the change in mean diameter, minimum diameter, percentage stenosis and the need for angioplasty was less with simvastatin. No additional benefit was observed with enalapril therapy.[1][2][3]

References

  1. Teo KK, Burton JR, Buller CE; et al. (2000). "Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT)". Circulation. 102 (15): 1748–54. PMID 11023927. Unknown parameter |month= ignored (help)
  2. Crawford DW, Barndt R, Back LH (1976). "Surface characteristics of normal and atherosclerotic human arteries including observations suggesting interaction between flow and intimal morphology". Lab. Invest. 34 (5): 463–70. PMID 1271748. Unknown parameter |month= ignored (help)
  3. Teo KK, Burton JR, Buller C, Plante S, Yokoyama S, Montague TJ (1997). "Rationale and design features of a clinical trial examining the effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). SCAT Investigators". Can J Cardiol. 13 (6): 591–9. PMID 9215232. Unknown parameter |month= ignored (help)